公开(公告)号：US11878008B2

公开(公告)日：2024-01-23

申请号：US16805381

申请日：2020-02-28

Applicant: AMOREPACIFIC CORPORATION

Inventor： Gyeyoung Choi ,  Hyunjin Nam ,  Miyoung Park ,  Kyoungmi Jung ,  Jihae Lee ,  Chang Soon Choi ,  Youngho Park ,  Jong Hwa Roh ,  Eunsil Park ,  Jaehong Park ,  Kwanghyun Shin ,  Byoung Young Woo ,  Kiwha Lee ,  Wonkyung Cho ,  Joonho Choi

IPC: A61P17/04 ,  A61K31/44 ,  A61K9/00

CPC classification number: A61K31/44 ,  A61K9/0014 ,  A61P17/04

Abstract: Disclosed is a method for preventing or treating atopic dermatitis using TRPV1 receptor antagonist. More specifically, it may be possible to prevent and/or treat the atopic dermatitis without any side effects such as an increase in body temperature, epidermal atrophy, and the like by percutaneously administrating a composition for external use on the skin containing the TRPV1 receptor antagonist.

公开(公告)号：US11382900B2

公开(公告)日：2022-07-12

申请号：US16805202

申请日：2020-02-28

Applicant: AMOREPACIFIC CORPORATION

Inventor： Gyeyoung Choi ,  Hyunjin Nam ,  Miyoung Park ,  Kyoungmi Jung ,  Jihae Lee ,  Chang Soon Choi ,  Youngho Park ,  Jong Hwa Roh ,  Eunsil Park ,  Jaehong Park ,  Kwanghyun Shin ,  Byoung Young Woo ,  Kiwha Lee ,  Wonkyung Cho ,  Joonho Choi

IPC: A61K31/44 ,  A61K9/00 ,  A61K9/06

Abstract: Disclosed is a method for preventing or treating sleep disorders using TRPV1 receptor antagonist, (R)—N-[1-(3,5-difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide. The method of the present invention can effectively and safely prevent or treat sleep disorders accompanying pruritus caused by atopic dermatitis.

公开(公告)号：US10858315B2

公开(公告)日：2020-12-08

申请号：US16337729

申请日：2017-09-26

Applicant: AMOREPACIFIC CORPORATION

Inventor： Byoung Young Woo ,  Ki-Wha Lee ,  Jihae Lee ,  Chang Soon Choi ,  Miyoung Park ,  Young-Ho Park ,  Sarva Jayaprakash ,  Sridhar Regati ,  Mamidi Srinivas ,  Krushnakant Patel ,  M. Ramamohan

IPC: C07C311/08 ,  B01D9/00 ,  C07C303/44 ,  B01L9/00

Abstract: Disclosed in the present specification is a method capable of preparing N-[4-[(1R)-1-[[(R)-(1,1-dimethylethyl)sulfinyl]amino]ethyl]-2,6-difluorophenyl]-methanesulfonamide (INT028-2) with high optical purity, through the selection of Ellman-chiral auxiliaries and the recrystallization and separation of optical isomers. According to the above method, high-purity N-[4-[(1R)-1-[[(R)-(1,1-dimethylethyl)sulfinyl]amino]ethyl]-2,6-difluorophenyl]-methanesulfonamide with excellent quality can be produced at room temperature by improving cryogenic process conditions necessary for realizing high optical purity, and thus the trimming due to the process failure rate can be remarkably reduced.